DCF Tool


Jazz Pharmaceuticals plc – Pharmaceutical Preparation Manufacturing
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Analysis Results
Intrinsic Value $762.71
Latest Price $131.23
Relative Value 83% undervalued
Thoughts on this result? Let us know.
Cash Flow (Billions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 14.9%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 6.5%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 14.9%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2023 1.48 1.39
2024 1.71 1.5
2025 1.96 1.62
2026 2.25 1.75
2027 2.59 1.89
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 58.4 billion. This corresponds to a present value of 40.0 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 8.15 billion. Adding in the terminal value gives a total present value of 48.1 billion.

There are presently 63.1 million outstanding shares, so the intrinsic value per share is 762.71.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 2,606,140,000
Current Cash 881,482,000
Current Liabilities 933,193,000
Current Debt 31,000,000
Non-Cash Working Capital (NCWC) 822,465,000
Change in NCWC -419,118,000
EBIT 502,347,000
Tax Provision -158,645,000
Depreciation and Amortization 629,471,000
Capital Expenditure -54,046,000
Unlevered Free Cash Flow 658,654,000
Current Assets 2,611,334,000
Current Cash 591,448,000
Current Liabilities 809,303,000
Current Debt 31,000,000
Non-Cash Working Capital (NCWC) 1,241,583,000
Change in NCWC 942,207,000
EBIT 169,564,000
Tax Provision 216,116,000
Depreciation and Amortization 552,483,000
Capital Expenditure -45,532,000
Unlevered Free Cash Flow 1,618,722,000
Current Assets 2,839,568,000
Current Cash 2,132,769,000
Current Liabilities 653,745,000
Current Debt 246,322,000
Non-Cash Working Capital (NCWC) 299,376,000
Change in NCWC 77,555,000
EBIT 762,500,000
Tax Provision 33,517,000
Depreciation and Amortization 278,253,000
Capital Expenditure -128,004,000
Unlevered Free Cash Flow 896,391,418
Current Assets 1,630,268,000
Current Cash 1,077,344,000
Current Liabilities 364,490,000
Current Debt 33,387,000
Non-Cash Working Capital (NCWC) 221,821,000
Change in NCWC 124,538,000
EBIT 638,260,000
Tax Provision -73,154,000
Depreciation and Amortization 370,156,000
Capital Expenditure -40,135,000
Unlevered Free Cash Flow 1,092,819,000
Current Assets 1,234,005,000
Current Cash 824,622,000
Current Liabilities 345,487,000
Current Debt 33,387,000
Non-Cash Working Capital (NCWC) 97,283,000
Change in NCWC -16,617,000
EBIT 655,531,000
Tax Provision 80,162,000
Depreciation and Amortization 216,731,000
Capital Expenditure -20,370,000
Unlevered Free Cash Flow 735,611,312
Current Assets 968,277,000
Current Cash 601,035,000
Current Liabilities 293,947,000
Current Debt 40,605,000
Non-Cash Working Capital (NCWC) 113,900,000
Change in NCWC 13,106,000
EBIT 612,833,000
Tax Provision -47,740,000
Depreciation and Amortization 165,154,000
Capital Expenditure -28,950,000
Unlevered Free Cash Flow 762,143,000
Current Assets 748,069,000
Current Cash 425,963,000
Current Liabilities 257,406,000
Current Debt 36,094,000
Non-Cash Working Capital (NCWC) 100,794,000
Change in NCWC 20,967,000
EBIT 615,025,000
Tax Provision 135,236,000
Depreciation and Amortization 113,780,000
Capital Expenditure -157,832,000
Unlevered Free Cash Flow 435,618,482
Current Assets 1,257,667,000
Current Cash 988,785,000
Current Liabilities 226,642,000
Current Debt 37,587,000
Non-Cash Working Capital (NCWC) 79,827,000
Change in NCWC -44,603,000
EBIT 539,743,000
Tax Provision 106,399,000
Depreciation and Amortization 108,056,000
Capital Expenditure -35,958,000
Unlevered Free Cash Flow 435,501,895
Current Assets 1,015,845,000
Current Cash 684,042,000
Current Liabilities 216,801,000
Current Debt 9,428,000
Non-Cash Working Capital (NCWC) 124,430,000
Change in NCWC 94,773,000
EBIT 437,578,000
Tax Provision 94,231,000
Depreciation and Amortization 133,681,000
Capital Expenditure -36,347,000
Unlevered Free Cash Flow 357,619,621
Current Assets 864,617,000
Current Cash 636,504,000
Current Liabilities 204,028,000
Current Debt 5,572,000
Non-Cash Working Capital (NCWC) 29,657,000
Change in NCWC 27,131,000
EBIT 340,312,000
Tax Provision 91,638,000
Depreciation and Amortization 82,090,000
Capital Expenditure -11,276,000
Unlevered Free Cash Flow 336,988,901
Current Assets 551,572,000
Current Cash 387,196,000
Current Liabilities 191,538,000
Current Debt 29,688,000
Non-Cash Working Capital (NCWC) 2,526,000
Change in NCWC 14,163,000
EBIT 197,844,000
Tax Provision -83,794,000
Depreciation and Amortization 74,229,000
Capital Expenditure -22,476,000
Unlevered Free Cash Flow 263,760,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.